Do All Nodules Appearing in Patients Subsequent to Radiation Therapy to the Head and Neck Areas Require Excision?

Author(s):  
Joel I. Hamburger ◽  
J. Martin Miller ◽  
Michael Garcia
2020 ◽  
Vol 5 (1) ◽  
pp. 1-15
Author(s):  
Doha Abdel Gawad ◽  
Manal Fareed ◽  
Naser Abd El- Bary ◽  
Hanan Attallah

2005 ◽  
Vol 35 (11) ◽  
pp. 639-644 ◽  
Author(s):  
Yoshizumi Kitamoto ◽  
Tetsuo Akimoto ◽  
Hitoshi Ishikawa ◽  
Tetsuo Nonaka ◽  
Hiroyuki Katoh ◽  
...  

FACE ◽  
2021 ◽  
pp. 273250162110138
Author(s):  
Rebecca Knackstedt ◽  
Peter Taub ◽  
Gary Rogers ◽  
Brian Gastman

The mainstay of curative therapy for head and neck skin cancers relies upon surgery and/or radiation therapy. However, for some aggressive, non-resectable or recurrent tumors, systemic therapy is necessary. Recent emerging classes of drugs have shown to improve survival for high-risk, recurrent, and unresectable variants of these tumors. The goal of this paper is to review options for systemic therapies for head and neck skin cancers including melanoma, non-melanoma skin cancers and other rare and non-malignant tumors.


2000 ◽  
Vol 18 (7) ◽  
pp. 1458-1464 ◽  
Author(s):  
Branislav Jeremic ◽  
Yuta Shibamoto ◽  
Biljana Milicic ◽  
Nebojsa Nikolic ◽  
Aleksandar Dagovic ◽  
...  

PURPOSE: To investigate whether the addition of cisplatin (CDDP) to hyperfractionation (Hfx) radiation therapy (RT) offers an advantage over the same Hfx RT given alone in locally advanced (stages III and IV) squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: One hundred thirty patients were randomized to receive either Hfx RT alone to a tumor dose of 77 Gy in 70 fractions in 35 treatment days over 7 weeks (group I, n = 65) or the same Hfx RT and concurrent low-dose (6 mg/m2) daily CDDP (group II, n = 65). RESULTS: Hfx RT/chemotherapy offered significantly higher survival rates than Hfx RT alone (68% v 49% at 2 years and 46% v 25% at 5 years; P = .0075). It also offered higher progression-free survival (46% v 25% at 5 years; P = .0068), higher locoregional progression-free survival (LRPFS) (50% v 36% at 5 years; P = .041), and higher distant metastasis-free survival (DMFS) (86% v 57% at 5 years; P = .0013). However, there was no difference between the two treatment groups in the incidence of either acute or late high-grade RT-induced toxicity. Hematologic high-grade toxicity was more frequent in group II patients. CONCLUSION: As compared with Hfx RT alone, Hfx RT and concurrent low-dose daily CDDP offered a survival advantage, as well as improved LRPFS and DMFS.


1980 ◽  
Vol 90 (6) ◽  
pp. 930-945 ◽  
Author(s):  
James B. Snow ◽  
Richard D. Gelber ◽  
Simon Kramer ◽  
Lawrence W. Davis ◽  
Victor A. Marcial ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document